Cancer Research Campaign operation manual for control recommendations for products derived from recombinant DNA technology prepared for investigational administration to patients with cancer in phase I trials.
Begent
R H
RH
University Department of Clinical Oncology, Royal Free Hospital School of Medicine, London, U.K.
Chester
K A
KA
Connors
T
T
Crowther
D
D
Fox
B
B
Griffiths
E
E
Hince
T A
TA
Ledermann
J A
JA
McVie
J G
JG
Minor
P
P
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D003257:Consumer Product Safety; D004274:DNA, Recombinant; D004348:Drug Labeling; D006801:Humans; D011994:Recombinant Proteins / Q000302:isolation & purification / Q000627:therapeutic use*; D011995:Recombination, Genetic
D000970:Antineoplastic Agents; D004274:DNA, Recombinant; D011994:Recombinant Proteins